Abstract
The objective of this study was to explore the effects of proton pump inhibitors (PPIs) on the development and prognosis of lung cancer precise radiotherapy-induced radiation pneumonitis. Clinical materials of 84 lung cancer patients who had radiation pneumonitis after precise radiotherapy were retrospectively analyzed, and the patients were divided into PPI group and control group, according to whether or not PPIs were applied. The development and prognosis of patients and the effects of different doses of PPI on patient condition from two groups were compared. There were 57 PPI cases in PPI group and 27 cases in control group. Basic characteristics of patients were not statistically different between the two groups; however, white blood cell count, oxygenation indexes, blood gas pH, and lung imaging index were significantly different (p < 0.05), indicating that radiation pneumonitis tended to be more severe in PPI group. As regards effects of PPI on prognosis of two groups, remission rate of radiation pneumonia in PPI group was significantly less than that of the control group. Among 57 cases in PPI group, there were 31 patients applied with PPI ≤ 1DDD and 31 patients applied with PPI > 1DDD. In comparison of the various parameters of patients, 7 days after being applied with different doses of PPI, there were no significant differences between the parameters of radiation pneumonitis. PPIs should be cautiously utilized to avoid the effects of lung cancer radiotherapy-induced radiation pneumonia.
Highlights
Lung cancer is the leading cause of cancer-related mortality, with 1.6 million (13 %) newly diagnosed patients of total cases and 1.4 million (18 %) deaths worldwide in 2008 [1]
A review of pathologically proven lung cancer patients presenting in our hospital between 2008 and May 2013 was performed. 84 patients who had been diagnosed with Radiation pneumonitis (RP) after precise radiotherapy were selected
pump inhibitors (PPIs) are frequently applied to lung cancer patients in treatment of radiotherapy- and/or chemotherapy-induced gastric discomforts
Summary
Lung cancer is the leading cause of cancer-related mortality, with 1.6 million (13 %) newly diagnosed patients of total cases and 1.4 million (18 %) deaths worldwide in 2008 [1]. Current treatment options include surgical resection, chemotherapy, and radiation. These treatment modalities are proven to be effective in improving the survival rate, they are all associated with various adverse effects which could reduce the quality of life and lead to unsatisfactory prognosis. Radiation pneumonitis (RP) is the one of the most significant complications of acute treatment-related toxicities in lung cancer. It occurs in 5–15 % of people who go through radiation therapy for lung cancer. The occurrence is higher if chemotherapy is given at the same time [2, 3]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
